Know Cancer

forgot password

WCC #50 - Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Phase 1/Phase 2
18 Years
Not Enrolling
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

Thank you

Trial Information

WCC #50 - Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer


Phase I - Primary

- To determine the maximum tolerated dose of lenalidomide when combined with fixed dose
pegylated liposomal doxorubicin hydrochloride in women with recurrent ovarian
epithelial, fallopian tube, or primary peritoneal cancer.

Phase II - Define the best overall response induced by lenalidomide in recurrent ovarian
cancer patients


- To obtain preliminary information on toxicity, response, and time to progression
(duration of response) of these patients.

- Progression free survival

Phase I OUTLINE: This is a dose-escalation study of lenalidomide. Patients receive oral
lenalidomide once daily on days 1-28 and pegylated liposomal doxorubicin hydrochloride
intravenously (IV) on day 1. Treatment repeats every 28 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity.

Phase II OUTLINE: The phase II component will include patients with measurable disease per
Response Evaluation Criteria In Solid Tumors (RECIST) criteria treated at lenalidomide 10 mg
days 1-28 days of a 28 day cycle (Maximum Tolerated Dose from phase I) with liposomal
doxorubicin 40 mg/m^2 to determine efficacy and safety of the combination therapy.
(Effective with April 2010 revision)

After completion of study therapy, patients are followed periodically.

Inclusion Criteria:

- Histological diagnosis of epithelial ovarian cancer, fallopian tube cancer, or
primary peritoneal cancer which has recurred or is resistant to prior treatment with
at least one platinum based regimen and meeting at least one of the following

- Platinum refractory - progression during the first six cycles of first line
therapy with a platinum based regimen

- Platinum resistant - progression within 6 months of completing first line
platinum based chemotherapy

- Platinum sensitive - progression more than 6 months of completing first line
platinum based chemotherapy

- Disease that has progressed while receiving or recurred within 6 months of
completing platinum based second-line therapy Patients who have failed a second
line therapy more than 6 months after completing treatment or have had more than
2 prior chemotherapy regimens will not be eligible for this study.

- Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) criteria
defined as one or more lesions that can be accurately measured in at least one
dimension (longest diameter to be recorded) as > or = 20 mm with conventional
techniques (CT, PET/CT, MRI, X-ray) or as > or = 10 mm with spiral CT scan.

Patients entering the study during the dose escalation component who do not meet the
measurable disease requirement may enter with elevated CA 125 levels only if previously
normal or stable CA 125 levels are documented after the completion of the prior
chemotherapy regimen.

- Age > or = 18 years at the time of signing of consent form

- Gynecologic Oncology Group (GOG) performance status of < or = 2

- Laboratory test results within these ranges within 14 days prior to study

- Absolute neutrophil count > or = 1.5 x 10^9/L

- Platelet count > or = 100 x 10^9/L

- Serum creatinine < or = 1.5 mg/dL

- Total bilirubin < 1.2 mg/dL

- AST (SGOT) and ALT (SGPT) < or = 2 x upper limit of institutional normal (ULN)
or < or = 5 x ULN if hepatic metastases are present.

- The left ventricular ejection fraction must be at or above the lower institutional
limits of normal (as assessed by MUGA scan or echocardiogram) obtained within 28 days
prior to registration.

- Peripheral neuropathy ≤ grade 2 (CTCAE v 3.0).

- Patients who are taking a stable or decreasing dose of concomitant systemic steroids
during the study must agree to also take low dose aspirin and/or other
platelet-active, anti-thrombotic medication (medication[s] used will be decided by
the Investigator) while receiving study drug and for 30 days after study drug is

- All previous cancer therapy, including chemotherapy, hormonal therapy and surgery,
must have been discontinued at least 28 days prior to treatment in this study. Use of
thalidomide, or structurally related compounds, radiation, or biologic response
modifiers must be discontinued at least 2 weeks prior to treatment in this study.

- Progression free of prior malignancies for > or = 5 years with exception of currently
treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of
the cervix or breast.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
and again within 24 hours of starting lenalidomide and must either commit to
continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
birth control, one highly effective method and one additional effective method AT THE
SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also
agree to ongoing pregnancy testing. All patients must be counseled at a minimum of
every 28 days about pregnancy precautions and risks of fetal exposure.

- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
intolerant to ASA may use warfarin or low molecular weight heparin)

- Voluntary written informed consent before performance of any study-related procedure
not part of normal medical care, with the understanding that consent may be withdrawn
by the subject at any time without prejudice to future medical care.

- A female of childbearing potential is a sexually mature woman who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 24 consecutive months (i.e., has had menses at any
time in the preceding 24 consecutive months).

Exclusion criteria:

- Histologic diagnosis of borderline or low malignant potential epithelial carcinoma.

- Any serious medical condition, laboratory abnormality, or psychiatric illness that,
in the opinion of the investigator, would prevent the patient from signing the
consent form.

- Prior history of myocardial infarction, congestive heart failure, or arrhythmia
requiring medication. History of uncontrolled hypertension. History of systolic or
diastolic dysfunction. EKG evidence of ventricular hypertrophy, conduction
abnormality, or serious arrhythmia.

- History of deep vein thromboembolism (DVT) within the previous 6 months, history of
thrombocytopenia or bleeding disorders.

- Pregnant or breast feeding females. Lenalidomide is pregnancy category X.

- Any condition, including the presence of laboratory abnormalities, which places the
patient at unacceptable risk if she were to participate in the study or confounds the
ability to interpret data from the study.

- Use of any other experimental drug or therapy within 28 days of study registration.

- Known hypersensitivity reaction > grade 2 to thalidomide or structurally related

- The development of erythema nodosum if characterized by a desquamating rash while
taking thalidomide or similar drugs

- Any prior use of lenalidomide or liposomal doxorubicin

- Concurrent use of other anti-cancer agents or treatments

- Known positive for HIV or infectious hepatitis, type A, B or C

- Uncontrolled hyper- or hypo- calcemia, glycosemia or thyroidism

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose of Lenalidomide

Outcome Description:

Phase I of study: Lenalidomide at cohort specific assigned dose and schedule (starting at 10 mg by mouth per day on days 1-28) of a 28 day cycle with 40 mg/m^2 of liposomal doxorubicin given intravenously (IV) on day 1 of a 28 day cycle.

Outcome Time Frame:

Beginning from 1st Dose Until Not Tolerated - Phase I

Safety Issue:


Principal Investigator

Levi S. Downs, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota


United States: Food and Drug Administration

Study ID:




Start Date:

April 2009

Completion Date:

June 2014

Related Keywords:

  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Cavity Cancer
  • recurrent ovarian epithelial cancer
  • fallopian tube cancer
  • peritoneal cavity cancer
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms
  • Neoplasms, Glandular and Epithelial



University of Minnesota Medical Center - FairviewMinneapolis, Minnesota  55455